About Ribonuclease inhibitor
Ribonuclease inhibitor (RNH1) is a protein
from Homo sapiens identified by UniProt accession
P13489, 461 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | Ribonuclease inhibitor |
|---|
| UniProt accession | P13489 |
|---|
| Gene | RNH1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 461 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (60)
Diseases linked to this target (Open Targets).
- Encephalopathy · score 0.18
- Immature Reticulocyte Fraction Measurement · score 0.18
- reticulocyte measurement · score 0.16
- psoriasis · score 0.15
- reticulocyte count · score 0.14
- Blackfan-Diamond anemia · score 0.08
- cancer · score 0.08
- lung adenocarcinoma · score 0.07
- bladder transitional cell carcinoma · score 0.07
- COVID-19 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P13489-F1 | alphafold | PREDICTED | 96.44 | — |
Amino-acid sequence (461 residues)
MSLDIQSLDI QCEELSDARW AELLPLLQQC QVVRLDDCGL TEARCKDISS ALRVNPALAE LNLRSNELGD VGVHCVLQGL QTPSCKIQKL SLQNCCLTGA GCGVLSSTLR TLPTLQELHL SDNLLGDAGL QLLCEGLLDP QCRLEKLQLE YCSLSAASCE PLASVLRAKP DFKELTVSNN DINEAGVRVL CQGLKDSPCQ LEALKLESCG VTSDNCRDLC GIVASKASLR ELALGSNKLG DVGMAELCPG LLHPSSRLRT LWIWECGITA KGCGDLCRVL RAKESLKELS LAGNELGDEG ARLLCETLLE PGCQLESLWV KSCSFTAACC SHFSSVLAQN RFLLELQISN NRLEDAGVRE LCQGLGQPGS VLRVLWLADC DVSDSSCSSL AATLLANHSL RELDLSNNCL GDAGILQLVE SVRQPGCLLE QLVLYDIYWS EEMEDRLQAL EKDKPSLRVI S
Explore Ribonuclease inhibitor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets